PR: ImaBiotech to conduct Pilot Study with GSK to assess ImaBiotech’s Multimaging™ Technology
Lille, France –May, 2015 –ImaBiotech will be conducting a pilot study with pharmaceutical company GlaxoSmithKline (GSK) on mass spectrometric derived imaging technology in the ADME and Toxicology fields.
ImaBiotech, a leading service provider for MALDI imaging focuses on quantification challenges and volumetric imaging data interpretation via the development of specially adapted multimodal imaging methods and dedicated software, known as Multimaging™. Multimaging™, a new Advanced Technology, significantly increases the capacity of Quantitative Mass Spectrometry Imaging, and classical histology techniques. It has the capability to quantitatively analyze the distribution of drug, metabolites and biomarkers at cellular level. This technology offers the potential to accelerate drug pharmacokinetic, pharmacology and toxicity studies.
Dr Jonathan Stauber, CEO of ImaBiotech commented, “We are very pleased with the initiation of a pilot study with a major pharmaceutical company. GSK’s interest in assessing ImaBiotech’s Multimaging technology further underscores the expertise of ImaBiotech in the imaging field and the potential benefits that Multimaging technology offers.”